263 related articles for article (PubMed ID: 12015761)
21. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
Solsona E; Iborra I; Ricós JV; Monrós JL; Casanova J; Dumont R
J Urol; 1999 Apr; 161(4):1120-3. PubMed ID: 10081851
[TBL] [Abstract][Full Text] [Related]
22. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function.
Hinotsu S; Akaza H; Ohashi Y; Kotake T
Cancer; 1999 Nov; 86(9):1818-26. PubMed ID: 10547556
[TBL] [Abstract][Full Text] [Related]
23. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
24. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer.
Serretta V; Morgia G; Altieri V; Di Lallo A; Ruggiero G; Salzano L; Battaglia M; Falsaperla M; Zito A; Sblendorio D; Melloni D; Allegro R;
BJU Int; 2010 Jul; 106(2):212-7. PubMed ID: 20070299
[TBL] [Abstract][Full Text] [Related]
25. Single instillation of mitomycin C reduces 1st year recurrence following transurethral resection of non-muscle invasive bladder cancer.
Ather MH; Aziz S; Sulaiman MN
J Ayub Med Coll Abbottabad; 2007; 19(4):18-20. PubMed ID: 18693589
[TBL] [Abstract][Full Text] [Related]
26. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
Denzinger S; Burger M; Walter B; Knuechel R; Roessler W; Wieland WF; Filbeck T
Urology; 2007 Apr; 69(4):675-9. PubMed ID: 17445650
[TBL] [Abstract][Full Text] [Related]
27. [A randomized study of pirarubicin (THP) versus adriamycin (ADM) for intravesical instillation therapy against superficial bladder cancer].
Kawamura J; Tochigi H; Obata K; Ueda K; Otaguro K; Kuriyama M; Shinoda M; Naruse K; Murase T; Hasegawa Y
Hinyokika Kiyo; 1992 Mar; 38(3):379-85. PubMed ID: 1523998
[TBL] [Abstract][Full Text] [Related]
28. [Single instillation of epirubicin for the prophylaxis of recurrent primary superficial bladder carcinoma].
Liu B; Zhang Y; Wang Z; Ding Q; Chen B; Wang J; Jiang H
Zhonghua Wai Ke Za Zhi; 2002 Feb; 40(2):112-5. PubMed ID: 11955393
[TBL] [Abstract][Full Text] [Related]
29. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
[TBL] [Abstract][Full Text] [Related]
30. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
[TBL] [Abstract][Full Text] [Related]
31. [Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin].
Hinotsu S; Akaza H; Isaka S; Kagawa S; Koiso K; Kotake T; Machida T; Matsumura Y; Niijima T; Obata K; Ohashi Y; Ohe H; Shimazaki J; Tashiro K;
Gan To Kagaku Ryoho; 2002 Jan; 29(1):73-80. PubMed ID: 11816482
[TBL] [Abstract][Full Text] [Related]
32. [Effect of prophylactic treatment with intravesical epirubicin in recurrence of superficial bladder tumor].
Pérez Mestre M; Cuñat Albert E; Francisco Mingol V; Arrufat Boix JM; Gallego Gómez J
Arch Esp Urol; 1999 May; 52(4):345-50. PubMed ID: 10380324
[TBL] [Abstract][Full Text] [Related]
33. [Prevention of recurrence in non-invasive bladder carcinoma. Experiences with 400 patients].
Burk K; Troller RM; Pittner P
Urologe A; 1983 Sep; 22 Suppl():332-6. PubMed ID: 6356556
[TBL] [Abstract][Full Text] [Related]
34. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study.
Li NC; Ye ZQ; Na YQ;
Chin Med J (Engl); 2013; 126(15):2805-9. PubMed ID: 23924446
[TBL] [Abstract][Full Text] [Related]
36. [Prophylactic effect of UFT in combination with intravesical chemotherapy on the recurrence of superficial bladder tumor].
Yoshida O; Kakehi Y; Nishio Y; Tomoyoshi T; Konami T; Usui T; Igawa M; Takenaka I; Fujita K
Hinyokika Kiyo; 1992 Dec; 38(12):1437-43. PubMed ID: 1288238
[TBL] [Abstract][Full Text] [Related]
37. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial.
Ito A; Shintaku I; Satoh M; Ioritani N; Aizawa M; Tochigi T; Kawamura S; Aoki H; Numata I; Takeda A; Namiki S; Namima T; Ikeda Y; Kambe K; Kyan A; Ueno S; Orikasa K; Katoh S; Adachi H; Tokuyama S; Ishidoya S; Yamaguchi T; Arai Y
J Clin Oncol; 2013 Apr; 31(11):1422-7. PubMed ID: 23460707
[TBL] [Abstract][Full Text] [Related]
38. [Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: a prospective controlled study].
Maekawa S; Suzuki H; Ohkubo K; Aoki Y; Okada T; Maeda H; Ogura K; Arai Y
Hinyokika Kiyo; 2000 May; 46(5):301-6. PubMed ID: 10876750
[TBL] [Abstract][Full Text] [Related]
39. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
[TBL] [Abstract][Full Text] [Related]
40. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
